Vasoplegia clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Angiotensin II in Liver Transplantation
open to eligible people ages 18 years and up
The purpose of this study is to determine the efficacy and safety of Angiotensin II as a second-line vasopressor (drug that raises the blood pressure) during liver transplantation.
San Francisco, California
Our lead scientists for Vasoplegia research studies include Michael P Bokoch, M.D., Ph.D..